Novogen Limited (NASDAQ:KZIA) Receives Average Rating of “Moderate Buy” from Brokerages

Novogen Limited (NASDAQ:KZIA) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $25.80.

KZIA has been the subject of a number of recent research reports. Laidlaw initiated coverage on shares of Novogen in a research report on Wednesday, April 15th. They issued a “buy” rating and a $25.00 target price for the company. Lake Street Capital began coverage on shares of Novogen in a research report on Thursday, June 11th. They set a “buy” rating and a $32.00 price target on the stock. BTIG Research reaffirmed a “buy” rating and set a $34.00 price objective on shares of Novogen in a research note on Wednesday, July 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a report on Friday, July 17th.

Novogen Price Performance

NASDAQ KZIA opened at $12.82 on Friday. The business has a fifty day moving average price of $13.11 and a 200 day moving average price of $10.23. Novogen has a one year low of $4.86 and a one year high of $17.40.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.